Edition:
India

Kyowa Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,090JPY
15 Nov 2019
Change (% chg)

¥40 (+1.95%)
Prev Close
¥2,050
Open
¥2,050
Day's High
¥2,094
Day's Low
¥2,050
Volume
1,254,100
Avg. Vol
1,316,930
52-wk High
¥2,462
52-wk Low
¥1,674

Latest Key Developments (Source: Significant Developments)

Kyowa Kirin Inc Says Nourianz (Istradefylline) Now Available In U.S. For Treatment Of Parkinson's Disease "Off" Episodes
Tuesday, 15 Oct 2019 

Oct 14 (Reuters) - Kyowa Kirin Inc::KYOWA KIRIN ANNOUNCES NOURIANZ (ISTRADEFYLLINE) NOW AVAILABLE IN THE U.S. FOR TREATMENT OF PARKINSON'S DISEASE "OFF" EPISODES.  Full Article

Ultragenyx And Kyowa Kirin Announce Intent To Submit Supplemental Biologics License Application To U.S. FDA For Crysvita In Tumor-Induced Osteomalacia
Tuesday, 10 Sep 2019 

Sept 10 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA KIRIN ANNOUNCE INTENT TO SUBMIT SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO U.S. FDA FOR CRYSVITA® (BUROSUMAB) IN TUMOR-INDUCED OSTEOMALACIA (TIO).ULTRAGENYX - DECISION TO SUBMIT SBLA FOR CRYSVITA FOLLOWS COMPLETION OF PRE-SBLA MEETING WITH FDA AND AGREEMENT ON FILING PACKAGE.ULTRAGENYX PHARMACEUTICAL - SUBMISSION OF CRYSVITA SBLA IS PLANNED FOR FIRST HALF OF 2020 AND WILL BE BASED ON CURRENT CLINICAL DATA PACKAGE.  Full Article

Kyowa Hakko Kirin Co Announces Results Of Early Retirement Offer
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Japan's Kyowa Hakko Kirin Co Ltd <4151.T>::ANNOUNCES RESULTS OF EARLY RETIREMENT OFFER.296 EMPLOYEES ACCEPTED OFFER TO RETIRE VOLUNTARILY EFFECTIVE JUNE 30.SEVERANCE AND OUTPLACEMENT EXPENSES TO BE ABOUT 5.1 BILLION YEN, RECORDED AS 'OTHER EXPENSES' IN Q1.CONSOLIDATED FORECASTS REMAIN UNCHANGED.  Full Article

Kyowa Kirin Announces FDA Acceptance Of Istradefylline (KW-6002) New Drug Application Resubmission In The US
Thursday, 4 Apr 2019 

April 4 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::KYOWA KIRIN ANNOUNCES FDA ACCEPTANCE OF ISTRADEFYLLINE (KW-6002) NEW DRUG APPLICATION RESUBMISSION IN THE US.KYOWA HAKKO KIRIN CO LTD - TARGET PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR A DECISION BY FDA IS IN AUGUST 27, 2019..  Full Article

Kyowa Hakko Kirin To Buy Back, Cancel Shares
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::TO BUY BACK UP TO 10.7 MILLION SHARES AT 2,111 YEN EACH BEFORE MARKET OPEN WEDS.TO CANCEL THOSE SHARES AND ADDITIONAL 25.78 MILLION SHARES FEB 19.  Full Article

Kyowa Hakko Kirin Co Offer Of Voluntary Early Retirement
Tuesday, 5 Feb 2019 

Kyowa Hakko Kirin Co Ltd <4151.T>::OFFER OF VOLUNTARY EARLY RETIREMENT.TARGET NUMBER OF APPLICANTS NOT SPECIFIED.  Full Article

Kirin Holdings To Buy 95 Percent Of Kyowa Hakko Bio For About 128 Billion Yen
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Kirin Holdings Co Ltd <2503.T>::NOTICE REGARDING ACQUISITION OF SHARES IN KYOWA HAKKO BIO.WILL ACQUIRE 95 PERCENT OF ALL OUTSTANDING SHARES IN KYOWA HAKKO BIO CO.ACQUISITION PRICE OF KYOWA HAKKO BIO ABOUT 128 BILLION YEN.DEAL EXPECTED TO CLOSE APRIL 24.  Full Article

Mei Pharma And Kyowa Hakko Kirin Announce License Agreement To Develop And Commercialize ME-401 In Japan
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::MEI PHARMA AND KYOWA HAKKO KIRIN ANNOUNCE LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE ME-401 IN JAPAN.MEI PHARMA INC - MEI TO RECEIVE $10 MILLION UPFRONT PAYMENT, PLUS MILESTONES AND TIERED ROYALTY PAYMENTS.MEI PHARMA INC - AGREEMENT GRANTS KYOWA HAKKO KIRIN EXCLUSIVE RIGHTS TO ME-401 TO DEVELOP AND COMMERCIALIZE ME-401 IN JAPAN.MEI PHARMA INC - KYOWA HAKKO KIRIN PLANS TO INITIATE A PHASE 1 STUDY IN JAPAN IN 2019.  Full Article

R&I affirms Kyowa Hakko Kirin's rating at "A+" and says stable outlook-R&I
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+"-R&I.Rating outlook stable-R&I.  Full Article

Ultragenyx, Kyowa Kirin Say Crysvita Met Main Goal Of Phase 3 Study
Thursday, 17 May 2018 

May 17 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA KIRIN ANNOUNCE TOPLINE PHASE 3 STUDY RESULTS DEMONSTRATING SUPERIORITY OF CRYSVITA® (BUROSUMAB) TREATMENT TO ORAL PHOSPHATE AND ACTIVE VITAMIN D IN CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA (XLH).ULTRAGENYX PHARMACEUTICAL INC - PHASE 3 STUDY OF CRYSVITA® (BUROSUMAB) MET ITS PRIMARY ENDPOINT.ULTRAGENYX PHARMACEUTICAL - PHASE 3 STUDY OF CRYSVITA SHOWED IMPROVEMENT IN IMPORTANT METABOLIC AND FUNCTIONAL MEASURES WITH CRYSVITA TREATMENT.  Full Article